Bedrijfsoverzicht
Journey Medical Corporation is a commercial-stage pharmaceutical entity dedicated to the development and commercialization of products designed to treat dermatological conditions within the United States market. The company operates within the broader Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on niche therapeutic areas rather than broad-spectrum mass-market medications. As of the latest available data, the corporation holds a market capitalization of $171.94M and generates annual revenue of $61.86M while employing a workforce of 58 individuals. These valuation and revenue figures indicate that Journey Medical Corporation occupies a mid-cap position in the specialty pharmaceutical landscape, possessing a significant asset base relative to its relatively small employee count, which suggests a high degree of operational leverage and potential for rapid scaling in specific dermatological niches.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $61.86M, yet this top-line growth resulted in a net income of $-11,431,000, revealing a cost structure where operating expenses significantly outpace gross profitability before interest and taxes. This disparity between revenue and net income highlights the substantial overhead burdens inherent in the commercialization phase of specialty drug manufacturing, where research, development, and marketing costs heavily impact the bottom line. The company's EBITDA stands at $-3,914,000, further illustrating that the business is currently generating negative operating cash conversion before financing costs. Furthermore, free cash flow is reported at $-8,353,750, which indicates that the company is burning cash to fund its operations and growth initiatives rather than generating surplus liquidity from current activities. Analyzing the margins, the gross margin sits at 66.2%, demonstrating strong pricing power or low cost of goods sold relative to sales, while the operating margin of -2.8% and profit margin of -18.5% reflect the high fixed costs and expense ratios typical of a company in a growth or transition phase. In terms of liquidity, the balance sheet shows $24.09M in cash against $25.40M in debt, creating a net debt position, although the debt-to-equity ratio of 79.73 suggests a highly leveraged capital structure relative to shareholders' equity. The current ratio of 1.79 indicates that the company holds sufficient current assets to cover its short-term liabilities with a buffer of approximately 79%, suggesting reasonable short-term liquidity despite the leverage. Return on Equity is -44.0% and Return on Assets is -5.8%, metrics that reveal that management has yet to generate positive returns on the capital invested by shareholders or utilized to operate the business, a common characteristic for specialty pharma firms still navigating commercial hurdles.
Waarderingsbeoordeling
The trailing P/E ratio is N/A due to the company's losses, whereas the forward P/E is listed as -86.17, a metric that implies the market is pricing in the expectation of a significant turnaround or a re-rating of earnings in the future based on projected profitability. The price-to-book ratio stands at 4.41, which indicates that the market is valuing the company at a substantial premium of more than four times its net asset value, suggesting high expectations for future drug sales or intellectual property monetization. Additionally, the price-to-sales ratio is 2.78 and the EV/EBITDA is -36.44, providing alternative valuation lenses that emphasize revenue generation potential rather than current profitability, as traditional earnings-based multiples are distorted by the negative earnings picture. Regarding price action, the 52-week high is $9.55 and the 52-week low is $4.31, meaning the stock trades within a range that defines its volatility and investor sentiment over the past year. The beta value of 1.04 indicates that the stock's price volatility moves slightly in tandem with the broader market, exhibiting a sensitivity that is marginally higher than the average market index but not significantly so.
Growth & Income
Revenue growth year-over-year is recorded at 18.1%, signaling a robust expansion in sales volume or pricing, whereas earnings growth is N/A due to the absence of positive earnings in the prior period to compare against. Since the company does not report positive earnings growth, the implication is that revenue expansion has not yet translated into profitability, a typical trajectory for specialty drug manufacturers awaiting market penetration or regulatory approvals. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available earnings, including the reported losses, are being reinvested back into the business to fund R&D and commercialization efforts rather than being distributed to shareholders. Consequently, the overall growth and income profile for Journey Medical Corporation is defined by aggressive top-line expansion funded by existing cash reserves and capital markets, with no current reliance on dividend income for investors seeking yield.